Complete Case: Amgen Whistleblowing Essay

put down and write up an executive summary on the case, including answers to the following questions. 1. How did Amgens un ethical behavior contribute to the problems with Medicaid kickbacks? 2. Why does the public consider this dirt to have an unethical dilemma? 3. Explain what is meant by whistleblowing?Include your opinions and pose every gaps between public expectations of ethical standards and universal professional codes of ethical standards. Case Amgen Whistleblowing CaseAmgen, a Thousand Oaks, Californiabased smart set, had the mucilaginous task of dealing with grammatical cases filed by 15 states in 2009 alleging a Medicaid kickback scheme.1 To entertain matters worse, two additional whistleblowing lawsuits were filed against the company in Ventura County. The complaints, which dont reckon related to the fraud alleged by the group of states, were brought by origin employees who said they had uncovered wrongdoing at the biotech giant and were terminated after(preno minal) they raised red flags to superiors. One employee alleged the company violated federal law by under- chronicleing complaints and problems with the companys drugs after they hit the market. The facts of that lawsuit are described below.Former Amgen employee Shawn OBrien sued Amgen for wrongful termination on October 9, 2009, alleging he was laid off in October 2007 in retaliation for fostering concerns about how the company reported complaints and problems with drugs already on the market. OBrien carryed as a senior project manager for Amgens Ongoing pitch Program, according to the lawsuit filed in Ventura County Superior Court. His job was to improve Amgens compliance processes with high inherent risk to public safety, major malefactor and civil liability, or both, according to the lawsuit. The lawsuit alleged that in April 2007, Amgens board of directors flagged the companys process for dealing with post-market complaints about drugs as a potential problem.Federal law re quires drug companies to track and report to the Food and Drug Administration any problems with their drugs after they hit the market. In June 2007, OBrien was put on the case. He soon uncovered facts that Amgen was non adequately and consistently identifying phone calls or mail related to post-marketing inauspicious events of product complaints. That year, OBrien warned the company about the seriousness of the issues but, he claims, the company would not take any action or offer any support. In August 2007, OBrien took his complaint to a senior executive/corporate officer (unnamed) and warned that Amgens process for dealing with post-market problems wasnt adequate.In early September of 2007, OBriens managers instructed him to stop all work and not discuss the issues any further with anyone. Approximately four weeks later(prenominal) he was informed that he was being terminated as disrupt of Amgens October 12, 2007, reduction in the work force.